Notch signalling cascade and proinflammatory mediators in peri-implant lesions with different RANKL/OPG ratios-An observational study.


Journal

Journal of periodontal research
ISSN: 1600-0765
Titre abrégé: J Periodontal Res
Pays: United States
ID NLM: 0055107

Informations de publication

Date de publication:
Apr 2023
Historique:
revised: 24 10 2022
received: 18 07 2022
accepted: 29 12 2022
pubmed: 9 1 2023
medline: 21 3 2023
entrez: 8 1 2023
Statut: ppublish

Résumé

Notch signaling pathway has been linked to bone loss in periodontitis and peri-implantitis. This research aimed to determine the Notch signaling molecules expression levels (Notch1, Notch2, Jagged1, Hes1, and Hey1), along with bone remodeling mediators (RANKL and OPG) and proinflammatory cytokines (TNF-α, IL-17, IL-1β, and IL-6) in patients with peri-implant diseases. The aforementioned markers' expression was evaluated in patients with different RANKL/OPG ratios. Fifty patients with peri-implantitis (PI group) and 45 patients with peri-implant mucositis (PM group) were enrolled. Relative gene expression levels of investigated molecules were determined by reverse transcriptase-real-time polymerase chain reaction. On the basis of RANKL/OPG ratio, all peri-implant lesions were divided into subgroups: RANKL-predominant (RANKL > OPG) and OPG-predominant (RANKL < OPG). Clinical periodontal parameters (probing depth-PD, bleeding on probing-BOP, clinical attachment level-CAL and plaque index-PLI), were recorded for each patient around every tooth, and around placed implants (PDi, BOPi, CALi, PLIi). RANKL-predominant PM patients exhibited higher expression levels of Notch2 (p = .044) and Hey1 (p = .005) compared to OPG-predominant lesions. In all RANKL-predominant cases, Hey1 (p = .001), IL-1β (p = .005), IL-6 (p = .002) were overexpressed in PI comparing to PM, accompanied with significantly higher PDi, CALi and PLIi in PI than PM (p = .001, p = .001 and p = .009). Notch2 upregulation in RANKL-predominant PM lesions could be an important contributor to alveolar bone resorption and represent a predictor of PM to PI transition. Similarly, the overexpression of IL-1β and IL-6 might provide an osteoclastogenic environment in PI RANKL-predominant lesions.

Sections du résumé

BACKGROUND & OBJECTIVE OBJECTIVE
Notch signaling pathway has been linked to bone loss in periodontitis and peri-implantitis. This research aimed to determine the Notch signaling molecules expression levels (Notch1, Notch2, Jagged1, Hes1, and Hey1), along with bone remodeling mediators (RANKL and OPG) and proinflammatory cytokines (TNF-α, IL-17, IL-1β, and IL-6) in patients with peri-implant diseases. The aforementioned markers' expression was evaluated in patients with different RANKL/OPG ratios.
METHODS METHODS
Fifty patients with peri-implantitis (PI group) and 45 patients with peri-implant mucositis (PM group) were enrolled. Relative gene expression levels of investigated molecules were determined by reverse transcriptase-real-time polymerase chain reaction. On the basis of RANKL/OPG ratio, all peri-implant lesions were divided into subgroups: RANKL-predominant (RANKL > OPG) and OPG-predominant (RANKL < OPG). Clinical periodontal parameters (probing depth-PD, bleeding on probing-BOP, clinical attachment level-CAL and plaque index-PLI), were recorded for each patient around every tooth, and around placed implants (PDi, BOPi, CALi, PLIi).
RESULTS RESULTS
RANKL-predominant PM patients exhibited higher expression levels of Notch2 (p = .044) and Hey1 (p = .005) compared to OPG-predominant lesions. In all RANKL-predominant cases, Hey1 (p = .001), IL-1β (p = .005), IL-6 (p = .002) were overexpressed in PI comparing to PM, accompanied with significantly higher PDi, CALi and PLIi in PI than PM (p = .001, p = .001 and p = .009).
CONCLUSIONS CONCLUSIONS
Notch2 upregulation in RANKL-predominant PM lesions could be an important contributor to alveolar bone resorption and represent a predictor of PM to PI transition. Similarly, the overexpression of IL-1β and IL-6 might provide an osteoclastogenic environment in PI RANKL-predominant lesions.

Identifiants

pubmed: 36617525
doi: 10.1111/jre.13096
doi:

Substances chimiques

Cytokines 0
Dental Implants 0
Interleukin-6 0
Receptors, Notch 0
RANK Ligand 0
TNFRSF11B protein, human 0
Osteoprotegerin 0

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

360-368

Subventions

Organisme : Ministry of Education, Science and Technological Development of Republic of Serbia
ID : 451-03-68/2022-14/200129

Informations de copyright

© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Derks J, Tomasi C. Peri-implant health and disease. A systematic review of current epidemiology. J Clin Periodontol. 2015;42(Suppl 16):S158-S171.
Schwarz F, Derks J, Monje A, Wang HL. Peri-implantitis. J Periodontol. 2018;89:S267-S290. doi:10.1002/jper.16-0350
Heitz-Mayfield LJA, Salvi GE. Peri-implant mucositis. J Clin Periodontol. 2018;45:S237-S245.
Darveau RP. Periodontitis: a polymicrobial disruption of host homeostasis. Nat Rev Microbiol. 2010;8(7):481-490. doi:10.1038/nrmicro2337
Heitz-Mayfield L, Lang NP. Comparative biology of chronic and aggressive periodontitis vs. peri-implantitis. Periodontol 2000. 2000;2010(53):167-181.
Salvi GE, Lang NP. Diagnostic parameters for monitoring peri-implant conditions. Int J Oral Maxillofac Implants. 2004;19(7):116-127.
Tompkins KA. The osteoimmunology of alveolar bone loss. Connect Tissue Res. 2016;57(2):69-90.
Taubman MA, Valverde P, Han XZ, Kawai T. Immune response: the key to bone resorption in periodontal disease. J Periodontol. 2005;76(11):2033-2041.
Choi Y, Woo KM, Ko SH, et al. Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8+ T cells. Eur J Immunol. 2001;31(7):2179-2188.
Belibasakis GN, Bostanci N. The RANKL-OPG system in clinical periodontology. J Clin Periodontol. 2012;39(3):239-248.
Bostanci N, Ilgenli T, Emingil G, et al. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: implications of their relative ratio. J Clin Periodontol. 2007;34(5):370-376.
Liu Y, Liu Q, Li Z, et al. Long non-coding RNA and mRNA expression profiles in peri-implantitis vs periodontitis. J Periodontal Res. 2020;55(3):342-353.
Milinkovic I, Djinic Krasavcevic A, Nikolic N, et al. Notch down-regulation and inflammatory cytokines and RANKL overexpression involvement in peri-implant mucositis and peri-implantitis: a cross-sectional study. Clin Oral Implants Res. 2021;32(12):1496-1505.
Rakic M, Lekovic V, Nikolic-Jakoba N, Vojvodic D, Petkovic-Curcin A, Sanz M. Bone loss biomarkers associated with peri-implantitis. A cross-sectional study. Clin Oral Implants Res. 2013;24(10):1110-1116.
Duarte PM, Serrao CR, Miranda TS, et al. Could cytokine levels in the peri-implant crevicular fluid be used to distinguish between healthy implants and implants with peri-implantitis? A systematic review. J Periodontal Res. 2016;51(6):689-698.
Theodoridis C, Doulkeridou C, Menexes G, Vouros I. Comparison of RANKL and OPG levels in peri-implant crevicular fluid between healthy and diseased peri-implant tissues. A systematic review and meta-analysis. Clin Oral Investig. 2022;26(1):823-836.
Canalis E. Notch in skeletal physiology and disease. Osteoporos Int. 2018;29(12):2611-2621.
Kopan R, Ilagan MXG. The canonical notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137(2):216-233.
Zanotti S, Canalis E. Notch signaling and the skeleton. Endocr Rev. 2016;37(3):223-253.
Zhao BH. TNF and bone remodeling. Curr Osteoporos Rep. 2017;15(3):126-134.
Berglundh T, Armitage G, Araujo MG, et al. Peri-implant diseases and conditions: consensus report of workgroup 4 of the 2017 world workshop on the classification of periodontal and peri-implant diseases and conditions. J Periodontol. 2018;89:S313-S318.
Aloufi F, Bissada N, Ficara A, Faddoul F, Al-Zahrani MS. Clinical assessment of peri-implant tissues in patients with varying severity of chronic periodontitis. Clin Implant Dent Relat Res. 2009;11(1):37-40.
Polson AM. The research team, calibration, and quality assurance in clinical trials in periodontics. Ann Periodontol. 1997;2(1):75-82.
Dutzan N, Vernal R, Hernandez M, et al. Levels of interferon-gamma and transcription factor T-bet in progressive periodontal lesions in patients with chronic periodontitis. J Periodontol. 2009;80(2):290-296.
Mijailovic I, Nikolic N, Djinic A, et al. The down-regulation of notch 1 signaling contributes to the severity of bone loss in aggressive periodontitis. J Periodontol. 2020;91(4):554-561.
Bostanci N, Belibasakis GN. Gingival crevicular fluid and its immune mediators in the proteomic era. Periodontol 2000. 2018;76(1):68-84.
Nikolic N, Jakovljevic A, Carkic J, et al. Notch signaling pathway in apical periodontitis: correlation with bone resorption regulators and proinflammatory cytokines. J Endod. 2019;45(2):123-128.
Djinic Krasavcevic A, Nikolic N, Mijailovic I, et al. Impact of notch signalling molecules and bone resorption regulators on clinical parameters in periodontitis. J Periodontal Res. 2021;56(1):131-138.
Savage A, Eaton KA, Moles DR, Needleman I. A systematic review of definitions of periodontitis and methods that have been used to identify this disease. J Clin Periodontol. 2009;36(6):458-467.
Papapanou PN, Sanz M, Buduneli N, et al. Periodontitis: consensus report of workgroup 2 of the 2017 world workshop on the classification of periodontal and peri-implant diseases and conditions. J Periodontol. 2018;89:S173-S182.
Ainamo J, Bay I. Problems and proposals for recording gingivitis and plaque. Int Dent J. 1975;25(4):229-235.
Sanz M, Chapple IL. Clinical research on peri-implant diseases: consensus report of working group 4. J Clin Periodontol. 2012;39(Suppl 12):202-206.
Ramanauskaite A, Becker K, Schwarz F. Clinical characteristics of peri-implant mucositis and peri-implantitis. Clin Oral Implants Res. 2018;29(6):551-556.
Monje A, Amerio E, Farina R, et al. Significance of probing for monitoring peri-implant diseases. Int J Oral Implantol. 2021;14:385-399.
Ata-Ali J, Flichy-Fernandez AJ, Ata-Ali F, Penarrocha-Diago M. Clinical, microbiologic, and host response characteristics in patients with peri-implant mucositis. Int J Oral Maxillofac Implants. 2013;28(3):883-890.
Severino VO, Beghini M, de Araújo MF, et al. Expression of IL-6, IL-10, IL-17 and IL-33 in the peri-implant crevicular fluid of patients with peri-implant mucositis and peri-implantitis. Arch Oral Biol. 2016;72:194-199.
Dinarello CA. Proinflammatory cytokines. Chest. 2000;118(2):503-508.
Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med. 2006;203(12):2673-2682.
Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol. 2006;6(4):329-334.
Tanaka K, Hashizume M, Mihara M, Yoshida H, Suzuki M, Matsumoto Y. Anti-interleukin-6 receptor antibody prevents systemic bone mass loss via reducing the number of osteoclast precursors in bone marrow in a collagen-induced arthritis model. Clin Exp Immunol. 2014;175(2):172-180.
Konttinen YT, Ma J, Lappalainen R, et al. Immunohistochemical evaluation of inflammatory mediators in failing implants. Int J Periodontics Restorative Dent. 2006;26(2):135-141.
Severino VO, Napimoga MH, de Lima Pereira SA. Expression of IL-6, IL-10, IL-17 and IL-8 in the peri-implant crevicular fluid of patients with peri-implantitis. Arch Oral Biol. 2011;56(8):823-828.
Maier MM, Gessler M. Comparative analysis of the human and mouse Hey1 promoter: hey genes are new notch target genes. Biochem Biophys Res Commun. 2000;275(2):652-660. doi:10.1006/bbrc.2000.3354
Duan L, Ren YJ. Role of notch signaling in osteoimmunology-from the standpoint of osteoclast differentiation. Eur J Orthod. 2013;35(2):175-182. doi:10.1093/ejo/cjs002
Regan J, Long FX. Notch signaling and bone remodeling. Curr Osteoporos Rep. 2013;11(2):126-129.

Auteurs

Ana Djinic Krasavcevic (A)

Department of Periodontology and Oral Medicine, School of Dental Medicine, University of Belgrade, Belgrade, Serbia.

Nadja Nikolic (N)

Department of Human Genetics, School of Dental Medicine, University of Belgrade, Belgrade, Serbia.

Iva Milinkovic (I)

Department of Periodontology and Oral Medicine, School of Dental Medicine, University of Belgrade, Belgrade, Serbia.

Jelena Carkic (J)

Department of Human Genetics, School of Dental Medicine, University of Belgrade, Belgrade, Serbia.

Marija Jezdic (M)

Department of Periodontology and Oral Medicine, School of Dental Medicine, University of Belgrade, Belgrade, Serbia.

Sasha Jankovic (S)

Department of Periodontology and Oral Medicine, School of Dental Medicine, University of Belgrade, Belgrade, Serbia.

Zoran Aleksic (Z)

Department of Periodontology and Oral Medicine, School of Dental Medicine, University of Belgrade, Belgrade, Serbia.

Jelena Milasin (J)

Department of Human Genetics, School of Dental Medicine, University of Belgrade, Belgrade, Serbia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH